Cyproterone, Ethinyl Estradiol
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Combined contraceptive drug (estrogen + antiandrogen).
Combined low-dose monophasic contraceptive drug with anti-androgenic activity. The mechanism of action is due to its antiandrogenic steroid structure, cyproterone acetate, and oral estrogen, ethinyl estradiol. It blocks the androgen receptors, inhibits the secretion of pituitary gonadotropic hormones.
Cyproterone has the ability to competitively bind with natural androgen receptors (including testosterone, dihydroepiandrosterone, androstenedione), which are formed in small amounts in the body of women, mainly in the adrenal glands, ovaries and skin. By blocking androgen receptors in target organs, it reduces the effects of androgenization in women (due to the disruption of processes mediated by hormone-receptor complexes at the level of the main intracellular mechanisms). Along with antiandrogenic properties, it has a gestagenic activity, imitating the properties of imitating properties of the hormone of the yellow body. Inhibits the secretion of pituitary gonadotropic hormones and inhibits ovulation, which causes its contraceptive effect.
Ethinyl estradiol increases the central and peripheral effects of cyproterone on ovulation, maintains a high viscosity of the cervical mucus, which makes it difficult for spermatozoids to penetrate the uterine cavity and contributes to ensuring a reliable contraceptive effect.
- contraception in women with androgenization phenomena;
- treatment of androgen-dependent diseases / conditions in women ("vulgar" acne (acne papulopustulosa, acne nodulocystica); seborrhea; androgenic alopecia; hirsutism).
|ethinylestradiol micronized||35 mcg|
|cyproterone acetate micronized||2 mg|
Excipients: lactose monohydrate - 29.115 mg, corn starch - 20 mg, povidone K25 - 2.1 mg, talc - 1.65 mg, magnesium stearate - 100 μg.
The composition of the shell: sucrose - 19.637 mg, calcium carbonate - 8.402 mg, talc - 4.095 mg, titanium dioxide - 278 μg, povidone K90 - 200 μg, macrogol 6000 - 2.178 mg, glycerol 85% - 139 μg, iron dye oxide - 27 μg , mountain glycolic wax - 44 mcg.
Cyproterone, Ethinyl Estradiol is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Model Pure||Haupt Pharma Münster GmbH||Germany||pills|
|Diane-35||Bayer Pharma AG||Germany||dragee|
No customer reviews for the moment.
Dosage and Administration
Chloe drug® take orally 1 tablet per day. The pill is taken without chewing, and washed down with a small amount of liquid. While taking the drug does not matter, however, the subsequent reception should be made at the same selected hour, preferably after breakfast or dinner.
In the absence of taking any hormonal contraceptive drugs in the previous month. Chloe drug® Begin on the 1st day of the menstrual cycle (i.e., on the first day of menstrual bleeding) using a pill of the corresponding day of the week from the calendar package. It is allowed to start taking on the 2-5 day of the menstrual cycle, but in this case it is recommended to additionally use the barrier method of contraception during the first 7 days of taking pills from the first package.
A daily intake of the drug is carried out using pills from a calendar package sequentially in the direction of the arrow printed on the foil, until all the pills are taken. After all 21 pills are taken in yellow-orange color from the calendar package, the remaining white pills should be taken in the next 7 days. During the last 7 days of the treatment cycle (28 days), menstrual bleeding should occur (bleeding as a result of discontinuation of treatment). Menstrual-like bleeding usually begins 2-3 days after the 21st day of the CHLOE treatment cycle.®. The next package must be started the next day after the complete completion of taking the pills from the previous package, regardless of whether the bleeding continues or not.
When switching from combined contraceptive drugs (oral contraceptives (OCCs), vaginal ring or contraceptive patch). Chloe drug® should begin the day after taking the last active tablet of the previous drug, but in no case later than the next day after the usual 7-day break in the intake (for drugs containing 21 pills). Further, as described above. If the patient has taken a previous contraceptive daily for 28 days, take the Chloe drug.® should start after taking the last inactive pill. Chloe drug® Begin on the day of removal of the vaginal ring or contraceptive patch, but no later than the day when a new patch is to be inserted or a new patch is pasted.
When switching from contraceptives containing only gestagens ("mini-pili", injection forms, implants, progestogen-releasing intrauterine contraceptive). In the transition from the "mini-drink" taking the drug Chloe®You can start without a break.
When using injectable forms of contraceptives taking the drug Chloe® start from the day when the next injection should be done.
When moving from the implant - on the day of its removal. In all cases, you must use an additional barrier method of contraception during the first 7 days of taking the drug.
After an abortion in the first trimester of pregnancy, a woman can start taking the drug immediately. In this case, the woman does not need additional methods of contraception.
After delivery, in the absence of breastfeeding or abortion in the second trimester of pregnancy, the drug should be started on days 21-28. If the reception started later, you must use an additional barrier method of contraception during the first 7 days of taking the drug.
If a woman has been sexually active between the birth or abortion and the beginning of the administration of the drug CHLOE®, you must first eliminate the pregnancy or you must wait for the first menstruation.
Taking missed pills
The woman should take the missed pill as soon as possible, the next pill is taken at the usual time. With a delay of less than 12 hours, the reliability of contraception is not reduced.If the delay in taking the pills is more than 12 hours, the reliability of contraception can be reduced. The more pills are missed and the closer the pass to the 7-day break in taking pills, the greater the likelihood of pregnancy. In this case, you can follow the following two basic rules:
The drug should never be interrupted for more than 7 days.
To achieve adequate suppression of the hypothalamic-pituitary-ovarian regulation requires 7 days of continuous administration of the drug.
Accordingly, the following recommendations can be given if the delay in taking the pills was more than 12 hours (the interval from the moment of taking the last tablet is more than 36 hours):
The first week of taking the drug
A woman should take the last missed pill as soon as she remembers (even if it means taking two pills at the same time). The next pill is taken at the usual time. Additionally, you should use a barrier method of contraception for the next 7 days. If sexual intercourse took place during the week before the tablet is missed, the likelihood of pregnancy must be considered.
Second week of taking the drug
A woman should take the last missed pill as soon as she remembers (even if it means taking two pills at the same time). The next pill is taken at the usual time.
Provided that the woman took the pills correctly within 7 days preceding the first missed pill, there is no need to use additional contraceptive measures. Otherwise, as well as skipping two or more pills, you must additionally use barrier methods of contraception (for example, a condom) for 7 days.
Third week of taking the drug
The risk of pregnancy increases due to the upcoming break in taking the pills, however, if within the 7 days preceding the first missed pill, all the pills were taken correctly, there is no need to use additional contraceptive methods.
A woman should take the last missed pill as soon as she remembers (even if it means taking two pills at the same time). The following pills are taken at the usual time, until the pills from the current packaging run out. The following packaging should begin immediately. "Cancellation" bleeding is unlikely until the pills from the second package run out, but there may be "spotting" discharge and "breakthrough" bleeding while taking the pills.
A woman may also stop taking pills from the current pack. She should then take a break for 7 days, including the day she misses the pill, and then start taking the pills from the new pack.
If a woman misses a pill, and then during a break in reception she has no “withdrawal” bleeding, it is necessary to exclude pregnancy.
Recommendations for gastrointestinal disorders
If the woman had vomiting within 3 to 4 hours after taking the drug, the absorption of the active substances may be incomplete. In this case, you need to focus on the recommendations when skipping the pill.
Change the day of menstrual bleeding
In order to delay the onset of menstrual bleeding, a woman should continue taking the pills from the new package immediately after taking all the pills from the previous package, without interrupting the reception. pills from this new package can be taken as long as the woman wants (until the package is finished). On the background of taking the drug from the second package, women may experience "spotting" discharge or "breakthrough" uterine bleeding. Resume Chloe drug® from the new pack follows the usual 7-day break.
In order to postpone the day of the onset of menstrual bleeding to another day of the week, a woman should shorten the next break in taking the pills for as many days as she wants. The shorter the interval, the higher the risk that she will not have “withdrawal” bleeding and, in the future, there will be “spotting” spotting and “breakthrough” bleeding while taking the second pack (just like when she would like to delay onset of menstrual bleeding).
In the treatment of hyperandrogenic conditions, the duration of treatment is determined by the severity of the disease. After the symptoms disappear, it is recommended to take the drug for at least another 3-4 months. In the event of a relapse in a few weeks or months after completion of the course, you can repeat the treatment with the drug CHLOE®. In the case of resuming the drug (after a four-week break and more), you should take into account the increased risk of VTE (see also the section "Special instructions" and "With caution").
Kids and teens
Chloe drug® shown only after the onset of menarche.
Not applicable. Chloe drug® not shown after menopause. Patients with hepatic impairment
Chloe drug® contraindicated in women with severe liver disease until the liver function returns to normal (see also the section "Contraindications").
Patients with kidney impairment
Chloe drug® not specifically studied in patients with impaired renal disease. The available data do not imply a change in treatment in such patients.
The side effects listed below are presented in accordance with the following gradations of the frequency of their occurrence: very often (≥ 1/10); often (≥ 1/100 to <1/10); infrequently (≥ 1/1000 to <1/100); rarely (≥ 1/10000 to <1/1000), very rarely (<1/10000), frequency is unknown (frequency cannot be estimated based on available data).
Nervous system disorders: often - headache; infrequently - migraine: frequency unknown - worsening of the course of epilepsy.
Violations on the part of the organ of vision: rarely - intolerance to contact lenses.
Disorders of the gastrointestinal tract: often - nausea, abdominal pain; infrequently - vomiting, diarrhea.
Disturbances of the skin and subcutaneous tissues: infrequently - rash, urticaria; frequency is unknown - erythema nodosum, erythema multiforme.
Metabolic and nutritional disorders: often - weight gain; infrequently - fluid retention; rarely - weight loss.
Immune system disorders: rarely, hypersensitivity reactions.
Disorders of the genitals and breast: often - pain / tenderness in the mammary glands, engorgement of the mammary glands; infrequently - increase in mammary glands; rarely - discharge from the vagina, discharge from the mammary glands *; frequency unknown - acyclic bleeding / bleeding (metrorrhagia).
Mental disorders: often - decrease in mood, mood swings; infrequently - decreased libido; rarely - increased libido; frequency unknown - worsening of the course of endogenous depression.
Vascular disorders: rarely - thromboembolism.
* In the course of post-marketing research, painful menstrual-like bleeding and the absence of menstrual-like bleeding were reported, the frequency of which could not be assessed.
The following serious adverse events have been reported in women who use COCs (which include Chloe®):
- Venous thromboembolic disorders.
- Arterial thromboembolic disorders.
- Increased blood pressure.
- Impaired glucose tolerance or effect on peripheral insulin resistance.
- Liver tumors (benign and malignant).
- Impaired liver function.
- In women with hereditary angioedema, exogenous estrogens can cause or exacerbate the symptoms of angioedema.
- The onset or worsening of conditions for which communication with the use of COCs (which include the drug Chloe®) is not indisputable: jaundice and / or itching associated with cholestasis; the formation of gallstones; porphyria; systemic lupus erythematosus; hemolytic uremic syndrome; chorea; herpes during a previous pregnancy; hearing loss associated with otosclerosis; Crohn's disease; ulcerative colitis; cervical cancer.
- Visual impairment.
- The frequency of diagnosis of breast cancer in women who apply COCs (which include the drug Chloe®), raised very slightly. Breast cancer is rarely observed in women under 40 years, the frequency excess is negligible relative to the overall risk of developing breast cancer. The causal relationship of breast cancer with the use of COC is not installed. For more information, see “Contraindications” and “Special Instructions”.
- simultaneous use with another hormonal contraceptive;
- thrombosis (venous and arterial) or thromboembolism at present or in history (including deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular disorders, for example, stroke);
- conditions preceding thrombosis (including angina, transient ischemic attacks);
- multiple or severe venous or arterial thrombosis risk factors (including complicated valvular defects, atrial fibrillation, cerebrovascular disease or coronary arteries, uncontrolled hypertension, severe dislipoproteinemia, subacute bacterial endocarditis, prolonged immobilization, surgery on the lower extremities, neurosurgical operations, extensive injuries, smoking after the age of 35, obesity with a body mass index of more than 30 kg / m2);
- identifying a genetic or acquired predisposition to venous or arterial thrombosis, such as resistance to activated protein C (APC), deficiency of antithrombin III, protein C deficiency, protein deficit S, hyperhomocysteinemia and the presence of antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
- diabetes mellitus with diabetic angiopathy;
- severe liver disease is currently or in history or marked abnormal liver function no earlier than 6 months after the normalization of liver function indicators;
- liver tumors (benign and malignant);
- hormone-dependent malignant tumors or suspicion of them, incl. tumors of the mammary gland or genital organs (including a history of);
- bleeding from the vagina of unknown etiology;
- pancreatitis with severe hypertriglyceridemia (including in history);
- the presence of a history of migraine, which was accompanied by focal neurological symptoms;
- breastfeeding period;
- pregnancy or suspicion of it;
- congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes);
- age over 40 years;
- lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
- Hypersensitivity to the drug.
If any of these conditions develop for the first time while taking the drug Chloe®, the drug should be immediately discontinued.
Chloe drug® not intended for use in men.
Chloe drug® must be used with caution in epilepsy, depression, ulcerative colitis, liver and gallbladder diseases, uterine myoma, mastopathy, chorea, tetany, porphyria, multiple sclerosis, varicose veins, tuberculosis, kidney disease, in adolescence (without regular ovulatory cycles) , dyslipoproteinemia, sickle cell anemia, idiopathic jaundice or itching during a previous pregnancy, otosclerosis with impairment of hearing during a previous pregnancy.
With the simultaneous use of Chloe ® with inducers of microsomal liver enzymes (hydantoins, barbiturates, primidone, CP, carbamazepine, and rifampicin; and, possibly, with oxcarbazepine, topiramate, felbamate and griseofulvin), the clearance of ethynylestradiol and cyprotroma and cyprotromatte and cyprotromatte and cyprotromat and cyprotromatte and cyprotromatte and cyprromatum and griseofulvin increase the clearance of ethynyl estradiol and cryproteam, cyprotromat, and cyprotromat and cyprotromatte, citropromatol, cyprotromat, and cyprotromatte, as well as ethylene oestradiol and citroprotease, as well as ethylene oestradiol, and cyprotromat and cryprophascin. contraceptive reliability.
When used simultaneously with ampicillin, rifampicin and tetracyclines, Chloe® contraceptive reliability decreases.
Pregnancy and Lactation
The drug is contraindicated in pregnancy, suspected pregnancy and during breastfeeding.
Before starting to use the drug Chloe® it is necessary to conduct a general medical examination (including the mammary glands and cytological examination of the cervical epithelium), to exclude pregnancy, disorders of the blood coagulation system. With prolonged use of the drug, prophylactic control examinations should be carried out every 6 months.
If there are risk factors, the potential risk and expected benefits of the therapy should be carefully evaluated and discussed with the woman before she decides to start taking the drug.
When weighting, amplification, or at the first manifestation of any of these conditions or risk factors may require the abolition of the drug.
Chloe drug use® leads to increased risk of venous thromboembolism (VTE), compared with the risk of women who do not take the drug. The additional risk of VTE is highest during the first year of the use of the drug Chloe®, or when resuming reception after a break lasting 4 weeks or more. Venous thromboembolism in 1-2% of cases can be fatal. The approximate frequency of VTE when taking COCs with a low dose of estrogen (less than 50 micrograms of ethinyl estradiol) is up to 4 per 10,000 women per year compared to 0.5–1 per 10,000 women not taking COCs. At the same time, the frequency of VTE when taking COC is less than the frequency of VTE associated with pregnancy (6 per 10,000 pregnant women per year).
Epidemiological studies have shown that the incidence of VTE is 1.5 to 2 times higher in women taking the drug Chloe®, in comparison with COC containing levonorgestrel, and is similar to COC containing desogestrel / gestoden / drospirenone.
Patients with polycystic ovary syndrome have an increased risk of developing cardiovascular disease.
Epidemiological studies have also shown a connection with the use of hormonal contraceptives with an increased risk of developing arterial thromboembolism (myocardial infarction, transient ischemic attacks).
Thrombosis of other vessels, namely, the veins and arteries of the liver, mesentery, kidneys, brain or retina, has been extremely rarely reported in individuals taking hormonal contraceptives.
The patient should be warned that if symptoms of venous or arterial thrombosis develop, one should immediately consult a doctor. These symptoms include unilateral pain in the lower limb and / or swelling; sudden severe chest pain radiating to the left arm or without irradiation; sudden shortness of breath; sudden coughing up any unusual, severe, prolonged headache; increased frequency and severity of migraine; sudden partial or complete loss of vision; diplopia; inarticulate speech or aphasia; dizziness; collapse with / or without partial seizure; weakness or significant loss of sensitivity, suddenly appearing on one side or in one part of the body; movement disorders; "Sharp" belly.
The risk of venous thromboembolism increases:
with increasing age;
when smoking (with intensive smoking and with increasing age, the risk is further increased, especially in women over 35 years old.Women over 35 should be strongly advised to stop smoking if they want to take CHLOE.®);
with a family history (i.e., with a history of cases of venous thromboembolism at a relatively young age among parents or close relatives). If a hereditary predisposition is suspected, a woman should consult with a specialist before making a decision about any hormonal contraception;
during prolonged immobilization, surgery on the lower limbs, neurosurgical operations or extensive trauma. In these situations, it is necessary to discontinue use (in the case of a planned operation no less than 4 weeks), and not to resume it until two weeks after the full restoration of motor activity. If the use of the drug Chloe® has not been terminated in advance, should consider antithrombotic therapy;
with obesity (body mass index more than 30 kg / m2).
The risk of arterial thromboembolic complications or disorders of cerebral circulation increases:
with increasing age;
when smoking (with intensive smoking and with increasing age, the risk is further increased, especially in women over 35 years old. Women over 35 should be strongly advised to stop smoking if they want to take the drug CHLOE®);
with valvular heart disease;
with atrial fibrillation;
with a family history (i.e., with a history of cases of arterial thrombosis at a relatively young age with parents or close relatives). If a hereditary predisposition is suspected, a woman should consult a specialist before making a decision about any hormonal contraception.
Peripheral circulatory disorders can also occur in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (namely, Crohn's disease or ulcerative colitis) and sickle cell anemia.
It is necessary to take into account the increased risk of thromboembolism in the postpartum period.
Increase in the frequency or severity of migraine attacks during the use of the drug Chloe® (which may be a precursor of cerebral blood circulation disturbance) is a reason for immediate discontinuation of the drug.
Concerning the potential role of varicose veins and superficial thrombophlebitis in the development of venous thromboembolism, there is no consensus.
Biochemical factors that may indicate hereditary or acquired susceptibility to venous or arterial thrombosis include antibodies to activated protein C (APS), hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, anti-phospholipid antibodies (anti-cardiolipin antibodies, antibodies C, deficiency of antibodies C, deficiency of antibodies C, deficiency of antibodies S (deficiency antibodies), anti-phospholipid antibodies (anti-cardiolipid antibodies, antibodies C, deficiency of antibodies .
When evaluating the risk / benefit ratio, the doctor should consider that appropriate treatment of the underlying pathology can reduce the risk of thrombosis. Women taking the drug Chloe®, should clarify the need for timely reports to your doctor about the case of the development of possible symptoms of thrombosis. In the case of thrombosis or suspicion of its occurrence, treatment with Chloe® should stop. Given the teratogenicity of coagulants (coumarins), you should start using adequate methods of contraception.
In women with hypertriglyceridemia, while taking COCs (if there is this condition in the family history), the risk of pancreatitis may increase.
The relationship between COK and arterial hypertension has not been established. In case of persistent arterial hypertension, the drug CHLOE® it is necessary to cancel and prescribe the appropriate antihypertensive therapy. Admission contraceptive can be continued with the normalization of blood pressure.
In the event of a liver dysfunction, it may be necessary to temporarily withdraw Chloe.® to normalize laboratory values. Recurrent cholestatic jaundice, which develops for the first time during pregnancy or a previous intake of sex hormones, requires discontinuation of COC.
Although COCs have an effect on insulin resistance and glucose tolerance, there is usually no need to correct the dose of hypoglycemic drugs in patients with diabetes. However, this category of patients must be under close medical supervision.
Women with a tendency to chloasma while taking COCs should avoid prolonged exposure to the sun and exposure to ultraviolet radiation.
If women with hirsutism have recently developed symptoms or have significantly increased, other factors, such as androgen-producing tumors, congenital dysfunction of the adrenal cortex should be considered when conducting a differential diagnosis.
Against the background of taking the drug Chloe® occasionally irregular bleeding ("spotting" or "breakthrough" bleeding) may occur, especially during the first months of therapy. Therefore, any irregular bleeding should be assessed only after an adaptation period of approximately 3 cycles.
If irregular bleeding recurs or develops after previous regular cycles, non-hormonal causes should be considered and adequate diagnostic measures should be taken to exclude malignant neoplasms (including diagnostic curettage of the uterus cavity) or pregnancy.
In some cases, “withdrawal” bleeding may not develop during a break in the pill. In the case of irregular pills or in the absence of two menstrual bleeding in a row, pregnancy should be excluded before continuing to take the drug.
It is possible to change the results of allergic skin tests, a decrease in the concentration of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Due to the fact that the contraceptive effect is fully manifested by the 7th day from the start of the drug intake, additional non-hormonal methods of contraception are recommended in the first week.
Prescribe the drug after childbirth in the absence of breastfeeding is recommended only after the completion of the first normal menstrual cycle.
Treatment must be stopped 3 months before the planned pregnancy.
In case of diarrhea and vomiting, the contraceptive effect is reduced (without discontinuing the drug, it is necessary to use additional non-hormonal methods of contraception).
There are reports of some increase in the risk of cervical cancer with prolonged use of COC. Connection with taking COC is not proven. It remains a controversial question to what extent these findings are associated with pathology of the cervix or with the characteristics of sexual behavior (rarer use of barrier methods of contraception). The most important risk factor for cervical cancer is persistent HPV infection. A meta-analysis of 54 epidemiological studies has shown that there is a slightly increased relative risk of developing breast cancer diagnosed in women taking COCs at the present time (relative risk 1.24). The increased risk gradually disappears within 10 years after discontinuation of these drugs. Due to the fact that breast cancer is rarely observed in women under 40 years of age, an increase in the number of breast cancer diagnoses in women who are taking COCs now or who have recently taken it is insignificant relative to the overall risk of this disease. His association with KOC is not proven. The observed increase in risk may also be due to an earlier diagnosis of breast cancer in women using COCs. In women who have ever used COC, earlier stages of breast cancer are detected than in women who have never used them.
In rare cases, against the background of the use of COCs, the development of liver tumors was observed, which in some cases led to life-threatening intra-abdominal bleeding. This should be considered when carrying out a differential diagnosis in the event of severe pain in the abdomen, enlarged liver or signs of intra-abdominal bleeding.
The use of COCs may affect laboratory results, including biochemical indicators of the performance of the liver, thyroid gland, adrenal glands and kidneys, the concentration of plasma proteins, for example, corticosteroid-binding globulin, as well as the lipid / lipoprotein composition of the blood, carbohydrate metabolism and blood coagulation parameters. However, deviations usually remain within the range of normal laboratory values.
Symptoms: nausea, vomiting, slight vaginal bleeding.
Treatment: conduct symptomatic therapy. There is no specific antidote.
- Brand name: Model Pure
- Active ingredient: Cyproterone, Ethinyl Estradiol
- Dosage form: Yellow-coated pills, round, biconvex.
- Manufacturer: Haupt Pharma Münster GmbH
- Country of Origin: Germany
- Simultaneous spectrophotometric determination of cyproterone acetate and ethinyl estradiol in tablets using continuous wavelet and derivative transform
- Therapy of androgenetic symptomatology with cyproterone acetate and ethinyl estradiol
- The effect of ethinyl estradiol–cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome
- Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol–cyproterone acetate
- Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component
- Combined use of metformin and ethinyl estradiol–cyproterone acetate in polycystic ovary syndrome
- Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome
- Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome
- Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial
- Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: A one-year randomized, prospective, comparative trial
- Oral contraceptives that contain ethinyl estradiol (0.035 mg) and cyproterone acetate (2 mg) inhibit leukocyte transmigration through endothelial cell monolayers
- Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome
- Development of a Validated Liquid Chromatography Method for the Simultaneous Determination of Ethinyl Estradiol, Cyproterone Acetate, and Norgestrel in Breast Milk Following Solid‐Phase Extraction
- Effect of ethinyl estradiol–cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with